China’s Qihan Biotech names Carl June to scientific advisory board

Hangzhou Qihan Biotech Co Ltd has appointed Carl June as cell therapy chair of its scientific advisory board to oversee strategic scientific initiatives and provide guidance on the development of new therapies. Dr June was leader of the University of Pennsylvania, US, team that developed the first chimeric antigen receptor (CAR) T cell therapy for a blood cancer.

Since 2017, six CAR T cell therapies have been approved by the US Food and Drug Administration, all for the treatment of blood cancers. Qihan Biotech is advancing genetically modified immune cell therapies and aims to develop allogeneic cell and gene therapy to deliver medicine to patients in need.

Qihan Biotech announced the appointment on 19 December 2024.